The impact of donor age on the outcome of adult living donor liver transplantation

Transplantation

Volumn 85, Issue 9, 2008, Pages 1240-1245

  Iwamoto, Takayuki ^a   Yagi, Takahito ^a   Umeda, Yuzo ^a   Sato, Daisuke ^a   Matsukawa, Hiroyoshi ^a   Matsuda, Hiroaki ^a   Shinoura, Susumu ^a   Sadamori, Hiroshi ^a   Mizuno, Kenji ^a   Yoshida, Ryuichi ^a   Tanaka, Noriaki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Donor age; Liver transplantation; Living donor

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BILIRUBIN; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STAT3 PROTEIN; STEROID; TACROLIMUS;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BILIRUBIN BLOOD LEVEL; DISEASE COURSE; DOWN REGULATION; FEMALE; GENE INDUCTION; GRAFT SURVIVAL; HUMAN; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECIPIENT; REPERFUSION; RETROSPECTIVE STUDY; UPREGULATION;

ADOLESCENT; ADULT; AGE FACTORS; BIOLOGICAL MARKERS; DEOXYGUANOSINE; HEPATECTOMY; HUMANS; LIVER; LIVING DONORS; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 43449132704     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816c7e90     Document Type: Article

References (44)

1. Alkofer B, Samstein B, Guarrera JV, et al. Extended-donor criteria liver allografts. Semin Liver Dis 2006; 26: 221.
2. Rustgi VK, Marino G, Halpern MT, et al. Role of gender and race mismatch and graft failure in patients undergoing liver transplantation. Liver Transpl 2002; 8: 514.
3. D'Alessandro AM, Kalayoglu M, Sollinger HW, et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991; 51: 157.
4. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcomes in over 500 patients. Ann Surg 2001; 234: 384.
5. Marino IR, Doyle HR, Alrighetti L, et al. Effect of donor age and sex on the outcome of liver transplantation. Hepatology 1995; 22: 1754.
6. Hoofnagle JH, Lombarbero M, Zetterman RK, et al. Donor age and outcome of liver transplantation. Hepatology 1996; 24: 89.
7. Kim do Y, Choi MS, Lee JH, et al. Older donor allografts are associated with poor patient survival after living donor liver transplantation for hepatitis B virus-related liver disease. Liver Int 2007; 27: 260.
8. Shiffman ML, Saab S, Feng S, et al. Liver and intestine transplantation in the United States 1995-2004. Am J Transplant 2006; 6(5 pt 2): 1170.
9. Jain A, Reyes J, Kashyap R, et al. Long term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232: 490.
10. Busutti RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003; 9: 651.
11. Wiesner RH, Shorr JS, Steffen BJ, et al. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11: 750.
12. Kuramitsu K, Egawa H, Keeffe EB, et al. Impact of age older than 60 years in living donor liver transplantation. Transplantation 2007; 84: 166.
13. Yoshizumi T, Taketomi A, Soejima Y, et al. Impact of donor age and recipient status on left-lobe graft for living donor adult liver transplantation. Transpl Int 2008; 21: 81.
14. Urata K, Kawasaki S, Matsunami H, et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995; 21: 1317.
15. Kawasaki S, Makuuchi M, Matsunami H, et al. Living related liver transplantation in adults. Ann Surg 1998; 227: 269.
16. Weisner R, Edwards E, Freeman R, et al. Model for end-stage liver disease and allocation of donor livers. Gastroenterology 2003; 124: 91.
17. Müller C, Dünschede F, Koch E, et al. Alpha-lipoic acid preconditioning reduces ischemia-reperfusion injury of the rat liver via the PI3-kinase/Akt pathway. Am J Physiol Gastrointest Liver Physiol 2003; 285: G769.
18. Carini R, Grazia De Cesaris M, Splendor R, et al. Role of phosphatidyinositol 3-kinase in the development of hepatocyte preconditioning. Gastroenterology 2004; 127: 914.
19. Levy DE, Lee CK. What does Stat3 do? J Clin Invest 2002; 109: 1143.
20. Lütticken C, Wegenka UM, Yuan J, et al. Association of transcription factor aprf and protein kinase jak1 with the interleukin-6 signal transducer gp130. Science 1994; 263: 89.
21. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415.
22. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse stat3 gene leads to earlyembryoniclethality. Proc Natl Acad Sci USA 1997; 94: 3801.
23. Li W, Liang X, Kellendonk C, et al. Stat3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 2002; 277: 28411.
24. Debonera F, Aldeguer X, Shen X, et al. Activation of interleukin-6/stat3 and liver regeneration following transplantation. J Surg Res 2001; 96: 289.
25. Matsumoto S, Hanai T, Matsuura T, et al. Can monitoring of serum 8-OHdG level for 2 hours after transplantation predict prognosis of the graft. Transplant Proc 2006; 38: 2014.
26. Takeuchi T, Nakajima M, Morimoto K. Relationship between the intracellular reactive oxygen species and the induction of oxidative DNA damage in human neutrophil-like cells. Carcinogenesis 1996; 17: 1543.
27. Nakajima M, Takeuchi T, Morimoto K. Determination of 8- hydroxydeoxyguanosine in human cells under oxygen-free conditions. Carcinogenesis 1996; 17: 787.
28. Richter C. Oxidative damage to mitochondrial DNA and its relationship to aging. Int J Biochem Cell Biol 1995; 27: 647.
29. Toyokuni S, Tanaka T, Hattori Y, et al. Quantitative immunohistochemical determination of 8-hydroxy-20-deoxyguanosine by a monoclonal antibody N45.1: Its application to ferric nitrilotriacetate induced renal carcinogenesis model. Lab Invest 1997; 76: 365.
30. Saito S, Yamauchi H, Hasui Y, et al. Quantitive determination of urinary-8-hydroxydeoxyguanosine (8-OHdG) by using ELISA. Res Commun Mol Pathol Pharmacol 2000; 107: 39.
31. Tsukamoto I, Nakata R, Kojo S, et al. Effect on aging on rat liver regeneration after partial hepatectomy. Biochem Mol Biol Int 1993; 30: 773.
32. Kimura F, Miyazaki M, Suwa T, et al. Reduction of hepatic acute phase response after partial hepatectomy in elderly patients. Res Exp Med (Berl) 1996; 196: 281.
33. Morioka D, Egawa H, Kasahara M, et al. Outcomes of adult-to-adult living donor liver transplantation. Ann Surg 2007; 245: 315.
34. Lee DS, Gil WH, Lee HH, et al. Factors affecting graft survival after living donor liver transplantation. Transplant Proc 2004; 36: 2255.
35. Saucedo LJ, Edgar BA. Why size matters: Altering cell size. Curr Opin Genet Dev 2002; 12: 565.
36. Tapon N, Moberg KH, Hariharan IK. The coupling of cell growth to the cell cycle. Curr Opin Cell Biol 2001; 13: 731.
37. Wells WA. Does size matter? J Cell Biol 2002; 158: 1156.
38. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell 2002; 111: 293.
39. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005; 24: 7391.
40. Darnell JE. Stats and gene regulation. Science 1997; 277: 1630.
41. Schuringa JJ, Jonk LJ, Dokter WH, et al. Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J 2000; 347(pt 1): 89.
42. Haga S, Terui K, Zhang HQ, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 2003; 112: 989.
43. Cahill A, Stabley GJ, Wang X, et al. Chronic ethanol consumption causes alterations in the structural integrity of mitochondrial DNA in aged rats. Hepatology 1999; 30: 881.
44. Lin PH, Lee SH, Su CP, et al. Oxidative damage to mitochondrial DNA in a trial muscle of patients with atrial fibrillation. Free Radic Biol Med 2003; 35: 1310.